Standout Papers

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer p... 2010 2026 2015 2020 2.3k
  1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial (2010)
    Johann S. de Bono, Stéphane Oudard et al. The Lancet
  2. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial (2019)
    R. Wendel Naumann, Antoine Hollebecque et al. Journal of Clinical Oncology

Immediate Impact

16 by Nobel laureates 15 from Science/Nature 76 standout
Sub-graph 1 of 17

Citing Papers

Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy
2023 Standout
How chemokines organize the tumour microenvironment
2023 Standout

Works of Jean-Pascal Machiels being referenced

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
2012

Author Peers

Author Last Decade Papers Cites
Jean-Pascal Machiels 1999 2365 443 1004 36 4.4k
Liji Shen 1240 2728 210 1099 35 3.4k
Sophie Postel‐Vinay 3110 1651 406 290 115 5.5k
John Gutheil 2262 809 378 1215 38 4.1k
Ingo Diel 4954 1164 902 1575 111 6.3k
Erika Hitre 4291 1410 769 376 59 5.4k
Marija Drobnjak 3250 1967 587 438 41 6.9k
Otilia Dalesio 4373 3819 1402 756 103 7.9k
Steinbjørn Hansen 1700 3036 295 1311 88 5.5k
P. Koralewski 4430 3406 907 375 58 6.9k
Michael N. Needle 2431 1804 638 421 71 5.1k

All Works

Loading papers...

Rankless by CCL
2026